Financial Data and Key Metrics Changes - Total revenue grew 32% to $18,500,000 compared to $14,000,000 in the same quarter last year [22] - Net income was $4,000,000, a significant improvement from a net loss of $2,900,000 in the prior year [27] - Adjusted EBITDA increased to $3,900,000 from $900,000 in the previous year [27] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue rose 25% to $15,400,000, driven by improvements in gross to net [22][9] - Pediatric portfolio net revenue increased 77% to $3,100,000, reflecting the success of a return to growth plan [14][22] Market Data and Key Metrics Changes - ADHD prescriptions were approximately 94,000 during the third quarter, indicating a recovery in the stimulant market [10] - The pediatric portfolio saw a sequential revenue increase of 27%, showcasing effective promotional strategies [14][22] Company Strategy and Development Direction - The company has focused on its prescription pharmaceutical business, halting clinical development and selling its consumer health business [7][19] - Future growth is expected to come from leveraging the A2 RxConnect platform and pursuing additional in-licensed or acquired products [9][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining growth in both ADHD and pediatric portfolios, citing effective optimization efforts [35][36] - The company is monitoring macro factors, including potential impacts from political changes regarding fluoride supplementation [50] Other Important Information - The company has achieved three consecutive quarters of positive net income and eight straight quarters of positive adjusted EBITDA [31] - Cash and cash equivalents were $18,200,000, with a focus on managing debt and operational efficiency [28][29] Q&A Session Summary Question: Were there any one-time effects in the ADHD or pediatric business this quarter? - Management confirmed that the growth was organic and driven by optimization efforts, with no one-time effects [34] Question: What are the expectations for the ADHD franchise moving forward? - Management expects continued growth, emphasizing the balance and prioritization across the product portfolio [35][36] Question: What is the potential for the pediatric business? - Management indicated realistic growth expectations but does not foresee reaching a $25,000,000 annual run rate [38][39] Question: What are the main factors affecting business development and valuations? - The main gating factor is finding the right asset that complements the company's capabilities, with valuations currently being higher due to market conditions [40][43] Question: What impact do tariffs have on the company? - Management stated that tariffs have a minimal impact as all ADHD products are manufactured in the US, with only small components sourced internationally [45][46] Question: Can you elaborate on the return to growth plan for the pediatric business? - The plan involved deploying more sales force resources to pediatric targets and improving payer coverage [53][54]